Literature DB >> 15335423

Angiogenic factors in the cerebrospinal fluid of patients with astrocytic brain tumors.

Einat Peles1, Zvi Lidar, Amos J Simon, Rachel Grossman, Dvora Nass, Zvi Ram.   

Abstract

OBJECTIVE: Gliomas account for most primary brain tumors in adults, and survival correlates with the grade and vascularity of the tumor. The degree of tumor-related angiogenesis seems to be a significant predictor of tumor progression, recurrence, and metastatic spread in a variety of malignant diseases, including brain tumors. Our study's objective was to quantify the levels of two angiogenic factors, basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF), in the cerebrospinal fluid (CSF) and serum of patients with gliomas and to correlate these levels with tumor grade, vascularity, and overall survival.
METHODS: Twenty-six patients with the diagnosis of cerebral glioma (19 high-grade, 7 low-grade) comprised the study group. Ten patients with communicating hydrocephalus served as controls. Levels of VEGF and bFGF in the CSF and serum were determined using enzyme-linked immunosorbent assay analysis. Tumor vascularity was graded qualitatively using immunohistochemical staining for CD34. Nonparametric statistical techniques were used for data analysis.
RESULTS: Median levels of bFGF and VEGF in the CSF were significantly higher in patients with high-grade glioma as compared with patients with low-grade glioma or hydrocephalus (bFGF levels, 52, 26, and 24 ng/ml, respectively, P < 0.0001; VEGF levels, 17.6, 7.2, and 8.3 ng/ml, respectively, P < 0.005). A significant correlation was found comparing CSF levels of bFGF with levels of VEGF (P < 0.001). The levels of the angiogenic factors in the CSF correlated with the degree of tumor vascularity and were adversely associated with patient survival. Serum levels of the angiogenic factors showed no correlation to tumor grade, vascularity, or survival.
CONCLUSION: Our data suggest that CSF levels of bFGF and VEGF may serve as an additional marker for tumor grading and vascularity and may help predict survival.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15335423     DOI: 10.1227/01.neu.0000134383.27713.9a

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  14 in total

Review 1.  Molecularly targeted therapies for malignant gliomas.

Authors:  Andreas A Argyriou; Haralabos P Kalofonos
Journal:  Mol Med       Date:  2009 Mar-Apr       Impact factor: 6.354

Review 2.  Circulating glioma biomarkers.

Authors:  Johan M Kros; Dana M Mustafa; Lennard J M Dekker; Peter A E Sillevis Smitt; Theo M Luider; Ping-Pin Zheng
Journal:  Neuro Oncol       Date:  2014-09-24       Impact factor: 12.300

3.  Angiogenesis induced by signal transducer and activator of transcription 5A (STAT5A) is dependent on autocrine activity of proliferin.

Authors:  Xinhai Yang; Dianhua Qiao; Kristy Meyer; Thomas Pier; Sunduz Keles; Andreas Friedl
Journal:  J Biol Chem       Date:  2011-12-23       Impact factor: 5.157

4.  Serum angiogenic profile of patients with glioblastoma identifies distinct tumor subtypes and shows that TIMP-1 is a prognostic factor.

Authors:  Matthew Crocker; Sue Ashley; Ian Giddings; Vladimir Petrik; Anthea Hardcastle; Wynne Aherne; Andy Pearson; B Anthony Bell; Stergios Zacharoulis; Marios C Papadopoulos
Journal:  Neuro Oncol       Date:  2010-12-16       Impact factor: 12.300

Review 5.  Proteomic analyses of CSF aimed at biomarker development for pediatric brain tumors.

Authors:  Nardin Samuel; Marc Remke; James T Rutka; Brian Raught; David Malkin
Journal:  J Neurooncol       Date:  2014-04-26       Impact factor: 4.130

6.  Synthesis and in vitro evaluation of [18F](R)-FEPAQ: a potential PET ligand for VEGFR2.

Authors:  Jaya Prabhakaran; Victoria Arango; Vattoly J Majo; Norman R Simpson; Suham A Kassir; Mark D Underwood; Hanish Polavarapu; Jeffrey N Bruce; Peter Canoll; J John Mann; J S Dileep Kumar
Journal:  Bioorg Med Chem Lett       Date:  2012-06-07       Impact factor: 2.823

7.  Overexpression of vascular endothelial growth factor indicates poor outcomes of glioma: a systematic review and meta-analysis.

Authors:  Wenjie Chen; Deshen He; Zuyun Li; Xin Zhang; Denghua Pan; Gang Chen
Journal:  Int J Clin Exp Med       Date:  2015-06-15

8.  Cerebrospinal fluid VEGF levels and angiogenic capacity as potential prognostic markers in patients with gliomas: a pilot study.

Authors:  Sergio Vera; Mariana Sinning; Marcela Vergara; David Lemus; Carlos Rosas
Journal:  J Neurooncol       Date:  2019-10-17       Impact factor: 4.130

9.  Liquid biopsies in patients with diffuse glioma.

Authors:  Myron G Best; Nik Sol; Sebastiaan Zijl; Jaap C Reijneveld; Pieter Wesseling; Thomas Wurdinger
Journal:  Acta Neuropathol       Date:  2015-02-27       Impact factor: 17.088

10.  Blood-Based Biomarkers for Glioma in the Context of Gliomagenesis: A Systematic Review.

Authors:  Hamza Ali; Romée Harting; Ralph de Vries; Meedie Ali; Thomas Wurdinger; Myron G Best
Journal:  Front Oncol       Date:  2021-06-04       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.